This article is more than 5 years old. Information may no longer be current.
PCV13 affects resistance patterns of S. pneumoniae
Click Here to Manage Email Alerts
DENVER — More than 40% of Streptococcus pneumoniae that cause serious infections in Canada are included in the current 13-valent pneumococcal conjugate vaccine, researchers reported here at the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy.
“In 2011 to 2012, PCV13 provided coverage of 44.3% of all invasive S. pneumoniae and 54.2% of multidrug-resistant S. pneumoniae,” Heather J. Adam, PhD, FCCM, of the University of Manitoba, and colleagues wrote. “Significant changes in the epidemiology and susceptibility testing patterns continue to occur in S. pneumoniae in Canada, warranting ongoing surveillance.”
Heather J. Adam
The analysis included two studies evaluating the serotypes of invasive S. pneumoniae circulating in Canada; the Baseline Epidemiology of S. pneumoniae Serotypes (BESST) and the S. Pneumoniae Serotyping and Antimicrobial Susceptibility Assessment for Vaccine Efficacy in Canada (SAVE). The SAVE study was initiated after introduction of PCV13 (Prevnar 13, Pfizer) in Canada.
Researchers found that, from 2011 to 2012, 5.1% of isolates were covered by the 7-valent pneumococcal conjugate vaccine (Prevnar 7, Pfizer), 24.1% by the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine, and 44.3% by PCV13.
Prevalence of serotypes changed significantly between BESST and SAVE for the following serotypes: 4 (P<.0001), 5 (P<.0001), 7F (P<.0001), 9V (P<.0001), 14 (P<.0001), 18C (P=.03), 19F (P=.01), 33A (P=.03) and 35A (P=.02).
Three percent of the S. pneumoniae isolated in BESST were multidrug-resistant, and 7% of the SAVE isolates were multidrug-resistant.
For more information:
Adam HJ. Abstract C2-533. Presented at: ICAAC 2013; Sept. 9-13, 2013; Denver.Disclosure: Adam reports no relevant financial disclosures.